B02 - Sphingolipid- and matrix-mediated signalling pathways in chronic inflammation and fibrosis of the kidney

This project aims at investigating the therapeutic potential of specific inhibitors of S1PR5, the Spns2 transporter and of a novel S1PR1 G protein-biased agonist for an antifibrotic effect in kidney injury models. Mechanistically, the decreased degradation of antifibrotic Smad7 due to sphingosin-mediated reduction of ubiquitin ligases will be elucidated. Further experiments will particularly address the impact of specific chain-lengths of S1P and the crosstalk of S1P and the proteoglycan biglycan in renal inflammation, resolution and fibrosis.

Links:

• Institute of General Pharmacology and Toxicology